MedPath

Tavokinogene telseplasmid

Generic Name
Tavokinogene telseplasmid
Drug Type
Biotech
CAS Number
1971880-37-1
Unique Ingredient Identifier
MF4P7VQ2K8
Background

Tavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.

Clinical Trials
Related News

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Phase 1
Withdrawn
Conditions
Coronavirus Infection
Interventions
Device: CELLECTRA® 2000
First Posted Date
2022-06-24
Last Posted Date
2022-11-17
Lead Sponsor
Inovio Pharmaceuticals
Registration Number
NCT05430958

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Phase 1
Active, not recruiting
Conditions
BRCA1/2 Mutation
Interventions
Device: Cellectra 2000
First Posted Date
2020-04-29
Last Posted Date
2025-04-29
Lead Sponsor
University of Pennsylvania
Target Recruit Count
44
Registration Number
NCT04367675
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC

Phase 1
Active, not recruiting
Conditions
HCC
Interventions
Device: CELLECTRA®2000 EP Device
First Posted Date
2020-01-31
Last Posted Date
2025-01-31
Lead Sponsor
Geneos Therapeutics
Target Recruit Count
36
Registration Number
NCT04251117
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

🇳🇿

Auckland Clinical Studies, Auckland, New Zealand

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Phase 2
Terminated
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Device: ImmunoPulse
Biological: CORVax
First Posted Date
2019-01-30
Last Posted Date
2023-05-09
Lead Sponsor
Chase Heaton, MD
Target Recruit Count
14
Registration Number
NCT03823131
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Phase 1
Active, not recruiting
Conditions
Urothelial Carcinoma
Interventions
Device: CELLECTRA™ 2000
First Posted Date
2018-04-19
Last Posted Date
2025-04-27
Lead Sponsor
Inovio Pharmaceuticals
Target Recruit Count
35
Registration Number
NCT03502785
Locations
🇺🇸

Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States

🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

and more 8 locations

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Phase 1
Active, not recruiting
Conditions
Glioblastoma
Interventions
Radiation: Radiation Therapy
First Posted Date
2018-04-09
Last Posted Date
2025-04-27
Lead Sponsor
Inovio Pharmaceuticals
Target Recruit Count
52
Registration Number
NCT03491683
Locations
🇺🇸

University of Pennsylvania Health System: Penn Medicine, Philadelphia, Pennsylvania, United States

🇺🇸

Rutgers University - Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

and more 18 locations

Trial of pIL-12/MK-3475 in Metastatic Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2015-07-09
Last Posted Date
2021-01-06
Lead Sponsor
University of California, San Francisco
Target Recruit Count
24
Registration Number
NCT02493361
Locations
🇺🇸

University of San Francisco, California, San Francisco, California, United States

🇺🇸

Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy